Immunotherapeutic strategies in kidney cancer-when TKIs are not enough

Nature Reviews Clinical Oncology

Volumn 6, Issue 8, 2009, Pages 478-487

  Biswas, Swethajit ^a   Eisen, Tim ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AS 1409; BEVACIZUMAB; CANCER VACCINE; CARBONATE DEHYDRATASE IX; DENILEUKIN DIFTITOX; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; IPILIMUMAB; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOCLONAL ANTIBODY G250; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; RENIALE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VITESPEN; ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CYTOKINE; PROTEIN KINASE INHIBITOR; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLITIS; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DYSPNEA; EFFECTOR CELL; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOPHYSITIS; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MELANOMA; NEUROTOXICITY; NONHUMAN; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT PLANNING; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; STATISTICS; T LYMPHOCYTE SUBPOPULATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; META-ANALYSIS AS TOPIC; NEOPLASM PROTEINS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTE SUBSETS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350010317     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.91     Document Type: Review

References (95)

1. UK Kidney Cancer statistics. Cancer Research UK [online], http://info.cancerresearchuk.org/ cancerstats/types/kidney/ (2008).
2. Cancer Facts & Figures 2008. American Cancer Society [online], http://www.cancer.org/ downloads/sTT/2008CAFFfinalsecured.pdf (2008).
3. Murai, M. & Oya, M. renal Cell carcinoma: etiology, incidence and epidemiology. Curr. Opin. Urol. 14, 229-233 (2004).
4. Montie, J. e. et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. 117, 272 (1977).
5. Dekernion, J. B., ramming, K. P. & smith, r. B. The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol. 120, 148-152 (1978).
6. Marcus, s. G. et al. regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 150, 463-466 (1993).
7. Fyfe, G. et al. results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
8. Jonasch, e. & Haluska, F. G. interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55 (2001).
9. Upton, M. P., Parker, r. A., Youmans, A., McDermott, D. F. & Atkins. M. B. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J. Immunother. 28, 488-495 (2005).
10. Atkins, M. et al. Carbonic anhydrase iX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer. Res. 11, 3714-3721 (2005).
11. Motzer, r. J. et al. sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
12. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
13. Lukashev, D., sitkovsky, M. & Ohta, A. From 'Hellstrom Paradox' to anti-adenosinergic cancer immunotherapy. Purinergic Signal. 3, 129-134 (2007).
14. Kavanaugh, D. Y. & Carbone, D. P. immunological dysfunction in cancer. Hematol. Oncol. Clin. North Am. 10, 927-952 (1996).
15. Pederson, A. e. & ronchese, F. CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion. J. Immune Based Ther. Vaccines 5, 1-6 (2007).
16. wang, r. F. regulatory T cells and toll-like receptors in cancer therapy. Cancer Res. 66, 4987-4990 (2006).
17. Kavanagh, B. et al. CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112, 1175-1183 (2008).
18. siddiqui, s. A. et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin. Cancer Res. 13, 2075-2081 (2007).
19. sitkovsky, M. & Lukashev, D. regulation of immune cells by local-tissue oxygen tension: HiF1 alpha and adenosine receptors. Nat. Rev. Immunol. 5, 712-721 (2005).
20. Kim, J. w. & Dang, C. v. Cancer's molecular sweet tooth and the warburg effect. Cancer Res. 66, 8927-8930 (2006).
21. Koukourakis, M., Giatromanolaki, A., simopoulos, C., Polychronidis, A. & sivridis, e. Lactate dehydrogenase 5 (LDH5) relates to upregulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin. Exp. Metastasis 22, 25-30 (2005).
22. Fischer, K. et al. inhibitory effect of tumor cellderived lactic acid on human T cells. Blood 109, 3812-3819 (2007).
23. Ohta, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006).
24. Novitskiy, s. v. et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822-1831 (2008).
25. Deaglio, s. et al. Adenosine generation catalysed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
26. raval, r. r. et al. Contrasting properties of hypoxia-inducible factor 1 (HiF-1) and HiF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 (2005).
27. Khan, Z. A. et al. eDB fibronectin and angiogenesis: a novel mechanistic pathway. Angiogenesis 8, 183-196(2005).
28. Amato, r. J. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther. 7, 1463-1469 (2007).
29. Bui, M. H. et al. Carbonic anhydrase iX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
30. Doran, B., rogers, P., Jones, D., Green, C. & Courtenay-Luck, N. evaluation of the potential for targeted therapy of renal carcinoma and metastatic melanoma with huBC1-huiL12 (As1409), a potent immunocytokine [abstract]. AACR Meeting Abstracts 922 (2007).
31. Johnson, B. J., Clay, T. M., Hobeika, A. C., Lyerly, H. K. & Morse, M. A. vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Ther. 7, 449-460 (2007).
32. Ye, F. et al. vascular endothelial growth factor (veGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (sTATs) via veGF receptor-2 (KDr) in human hemopoietic progenitor cells. Gynecol. Oncol. 94, 125-133 (2004).
33. Fujita, M. et al. inhibition of sTAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180, 2089-2098 (2008).
34. Thompson, r. H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174-17179 (2004).
35. Crispen, P. L. et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14, 5150-5157 (2008).
36. Biswas, s. K., sica, A. & Lewis, C. e. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180, 2011-2017 (2007).
37. Lin, e. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006).
38. sica, A. et al. Autocrine production of iL-10 mediates defective iL-12 production and NF-kB activation in tumor-associated macrophages. J. Immunol. 164, 762-767 (2000).
39. Nagaraj, s. & Gabrilovich, D. i. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68, 2561-2563 (2008).
40. shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007).
41. shojaei, F. & Ferrara, N. refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 68, 5501-5504 (2008).
42. Karin, M., Lawrence, T. & Nizet, v. innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823-835 (2006).
43. Lin, w. w. & Karin, M. A cytokine-mediated link between inate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175-1183 (2007).
44. Laheru, D. A., Pardoll, D. M. & Jaffee, e. M. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol. Cancer Ther. 4, 1645-1652 (2005).
45. Tseng, s. Y. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
46. rosenberg, s. A. interleukin 2 for patients with renal cancer. Nat. Clin. Pract. Oncol. 4, 497 (2007).
47. McDermott, D. F. et al. randomized phase iii trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
48. Yang, J. C. et al. randomized study of high-dose and low-dose interleukin-2 patients in patients with metastatic renal cell cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
49. Negrier, s. et al. Medroxyprogesterone, interferon alfa-2a, interferon-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110, 2460-2477 (2007).
50. Coppin, C. et al. immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 1, CD001425 (2005).
51. Flanigan, r. C. et al. Nephrectomy followed by interferon-á2b compared with interferon-á2b alone for metastatic renal cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
52. Mickisch, G. H. et al. radical nephrectomy plus interferon-á based immunotherapy compared with interferon-á alone in metastatic renal cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
53. Fleshner, N. et al. The role of cytoreductive nephrectomy in metastatic renal cell cancer: a clinical practice guideline. Cancer Care Ontario [online], http://www.cancercare.on.ca/pdf/ pebc3-8-3f.pdf (2006).
54. Gore, M. e. on behalf of the re04 investigators. interferon-á (iFN), interleukin-2 (iL2) and 5-fluorouracil (5FU) vs iFN alone in patients with metastatic renal cell carcinoma (mrCC): results of the randomized MrC/eOrTC reO4 trial [abstract]. ASCO Meeting Abstracts 26, 5039 (2008).
55. Aass, N. et al. randomized phase ii/iii trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the european Organization for research and Treatment of Cancer Genito-Urinary Tract Cancer Group (eOrTC 30951). J. Clin. Oncol. 23, 4172-4178 (2005).
56. escudier, B. et al. A randomized, controlled, double-blind phase iii study (AvOreN) of bevacizumab/interferon-á2a vs placebo/ interferon-á2a as first-line therapy in metastatic renal cell carcinoma [abstract]. ASCO Meeting Abstracts 25, 3 (2007).
57. rini, B. i. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
58. escudier, B. J. et al. Update on AvOreN trial in metastatic renal cell carcinoma (mrCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [abstract]. ASCO Meeting Abstracts 26, 5025 (2008).
59. Mekhail, T. M. et al. validation and extension of the Memorial sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
60. Jocham, D. et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with rCC after radical nephrectomy: phase iii, randomized controlled trial. Lancet 363, 594-599 (2004).
61. Doehn C., richter, A., Theodor, r. A., Lehmacher, w. & Jocham, D. Prolongation of progression-free and overall survival following an adjuvant vaccination with reniale® in patients with non-metastatic renal cell carcinoma: secondary analysis of a multicenter phase-iii trial. Deutscher Krebskongress [online], http://www.egms.de./en/meetings/ dkk2006/06dkk395.shtml (2006).
62. wood, C. et al. An adjuvant autologous therapeutic vaccine (HsPCC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase iii trial. Lancet 372, 145-154 (2008).
63. Donskov, F. & von der Maase, H. impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol. 24, 1997-2005 (2006).
64. van der vliet, H. J. et al. effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13, 2100-2108 (2007).
65. Pantuck, A. J. et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma [abstract]. ASCO Meeting Abstracts 23, 4535 (2005).
66. Hutson, T. e. & Quinn D. i. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin. Genitourin. Cancer 4, 181-186 (2005).
67. Yang, J. C. et al. ipilimumab (anti-CTLA antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007).
68. Denileukin Diftitox in Treating Patients with Metastatic Melanoma or Metastatic Kidney Cancer. ClinicalTrials.gov [online], http:// clinicaltrials.gov/show/NCT00082914 (2009).
69. Denileukin Diftitox and interleukin-2 in Treating Patients with Metastatic Kidney Cancer. ClinicalTrials.gov [online], http://clinicaltrials. gov/ show/NCT00278369 (2009).
70. Fricke, i. et al. vascular endothelial growth factortrap overcomes defects in dendritic cell differentiation but does not improve antigenspecific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007).
71. McDermott, D. F. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin. Cancer Res. 13, 716s-720s (2007).
72. Passalacqua, r. et al. Bevacizumab (B) plus lowdoses immunotherapy (iT) plus chemotherapy (CT) (BiC) in metastatic renal cell cancer (mrCC): Antitumor effects and variations of T-regulator cells (Treg) and other T-lymphocytes subsets. A study of the italian Oncology Group for Clinical research (GOirC) [abstract]. ASCO Meeting Abstracts 26, 5121 (2008).
73. ryan, C. w. et al. sorafenib plus interferon-á2b (iFN) as first-line therapy for advanced renal cell carcinoma (rCC): SwOG 0412 [abstract]. ASCO Meeting Abstracts 24, 4525 (2006).
74. Goldman, B. H. et al. Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (rCC): An analysis of swOG 0412 [abstract]. ASCO Meeting Abstracts 25, 5108 (2007).
75. Hipp, M. H. et al. sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-5620 (2008).
76. Bleumer, i. et al. A phase ii trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 (2004).
77. Bleumer, i. et al. A clinical trial with chimeric monoclonal antibody wX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J. Urol. 175, 57-62 (2006).
78. Monoclonal Antibody Therapy (rencarex® ) in Treating Patients who Have Undergone surgery for Non-Metastatic Kidney Cancer. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct/show/ NCT00087022 (2009).
79. As1409 (huBC1-huiL12), Antisoma [online], http://www.antisoma.com/asm/ products/ as1409/ (2007).
80. white, e. s., Baralle, F. e. & Muro, A. F. New insights into form and function of fibronectin splice variants. J. Pathol. 216, 1-14 (2008).
81. Bendall, J. K., Heymes, C., ratajczak, P. & samuel, J. L. extracellular matrix and cardiac remodelling. Arch. Mal. Coeur Vaiss. 95, 1226-1229 (2002).
82. Trovax renal immunotherapy survival Trial. ClinicalTrials.gov [online], http://clinicaltrials.gov/ ct2/show/NCT00397345 (2008).
83. Hernandez-McClain, J. et al. vaccination of renal cell cancer (rCC) patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (Trovax [T]) administered + low dose interleukin-2 (iL-2): A phase ii trial [abstract]. ASCO Meeting Abstracts 26, 5101 (2008).
84. Uemura, H. et al. A phase i trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. 12, 1768-1775 (2006).
85. Lens, M., Ferrucci, P. F. & Testori, A. Anti-CTLA4 Monoclonal Antibody ipilimumab in the Treatment of Metastatic Melanoma: recent Findings. Recent Pat. Anti-Cancer Drug Discov. 3, 105-113 (2008).
86. Finke, J. H. et al. sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14, 6674-6682 (2008).
87. van Cruijsen, H. et al. sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14, 5884-5892 (2008).
88. Biswas, s. et al. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14, 52-59 (2009).
89. Biswas, s. et al. Adjuvant therapies in primary clear-cell renal carcinoma; in recent advances in renal cell carcinoma (rCC). Int. Oncol. Updat. 53-77 (2008).
90. rini, B. i. et al. Allogenic stem-cell transplantation of rCC after non-myeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20, 2017-2024 (2002).
91. Takahashi, Y. et al. regression of human kidney cancer following allogenic stem cell transplantation is associated with recognition of an Herv-e antigen by T-cells. J. Clin. Invest. 118, 1099-1109 (2008).
92. National Cancer institute Clinical Trials. National Cancer Institute [online], http://www.cancer.gov/ CLiNiCALTriALs (2009).
93. June, C. H. Adoptive T-cell therapy for cancer in the clinic. J. Clin. Invest. 117, 1466-1476 (2007).
94. Manegold, C. et al. randomized phase ii trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3979-3986 (2008).
95. Murillo, O. et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin. Cancer Res. 9, 5454-5464 (2003).